NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.
RSS Feed for NewMediaWireNovember 9, 2025 — DALLAS, TX - November 9, 2025 (NEWMEDIAWIRE) - More than 28 million people worldwide are living with heart valve disease, and the numbers are climbing. In the U.
November 9, 2025 — Research Highlights: Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels. 85% of all study participants had vitamin D levels below 40 ng/mL at enrollment, and nearly 52% of people in the treatment group needed to take more than 5,000 IU of vitamin D each day (more than six times the 800 IU daily value established by the FDA) to reach target blood levels of 40-80 ng/mL.
November 9, 2025 — Research Highlights: During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks. The results of the 200-person trial may challenge the common belief that caffeine may spur more abnormal heart rhythms such as AFib.
November 9, 2025 — Research Highlights: Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year. Weight loss was not thought to be the main reason metformin helped, since there was only a modest weight change among those taking the medication.
November 8, 2025 — Research Highlights: Earlier blood transfusion after major surgery – when hemoglobin was below 10 g/dL rather than beow 7 g/dl - did not affect the risk of severe complications, such as death, heart attack, need for a heart procedure, kidney failure or stroke. However, the timing of the blood transfusion may be associated with a lower risk of irregular heartbeat and heart failure among people with heart disease, according to a new study of U.
November 8, 2025 — Research Highlights: Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study. Researchers said these findings may suggest that ongoing blood-thinning medication may not be needed after an ablation procedure.
November 8, 2025 — Research Highlights: Standard care, which included medication for those eligible, was better than a promising minimally invasive procedure for people with irregular heart rhythms who had high stroke and bleeding risk. The procedure seals off a small pouch of heart tissue, where most blood clots form in people with irregular heartbeat.
November 8, 2025 — Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received a coronary stent was as effective as one year of continuous dual therapy for preventing stroke, heart attack and death. Participants treated with the one-month regimen experienced fewer bleeding problems than those in the year-long dual-treatment group.
November 8, 2025 — Research Highlights: For people who have experienced a heart attack or stroke, or who are at high risk of one and need further cholesterol lowering, a new daily pill may be a more convenient yet similarly effective option to injectable therapies. The oral medication, enlicitide, lowered LDL cholesterol by up to 60% and could eventually offer an option for people whose LDL levels remain above goal despite lifestyle changes and standard cholesterol medications like statins.
November 8, 2025 — Research Highlights: Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or stroke, the PCSK9 inhibitor evolocumab reduced the risk of coronary heart disease death, heart attack, or ischemic stroke by 25%. Participants taking evolocumab also had a 19% reduction in the risk of coronary heart disease death, heart attack, ischemic stroke or arterial revascularization over a median of more than four and a half years follow-up.
November 8, 2025 — Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by about 55%. Cholesterol and triglyceride levels began to drop within the two weeks after treatment, with effects sustained for at least 60 days of follow-up.
November 8, 2025 — Research Highlights: In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three different receptors linked to triglycerides: FGF21, glucagon and GLP-1 receptors.
November 7, 2025 — CALGARY, AB - November 7, 2025 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to announce, subject to regulatory approval, the appointment of Virginia Alling as an independent director.
November 7, 2025 — LOS ANGELES, CA - November 7, 2025 (NEWMEDIAWIRE) - Datavault AI (NASDAQ: DVLT), a leader in data monetization, credentialing and digital engagement, has partnered with Rodney’s Comedy Club to introduce a first-of-its-kind integration of its VerifyU, Joke Token, and ADIO(R) technologies - transforming live comedy into an interactive, data-driven experience. The collaboration makes Rodney’s the first U.
November 7, 2025 — LOS ANGELES, CA - November 7, 2025 (NEWMEDIAWIRE) - Forward Industries (NASDAQ: FORD), focused on building and managing the world's largest Solana treasury, recently made an initial treasury update announcement and revealed that the company’s total Solana (SOL) holdings have reached 6,871,599. 06 SOL (https://ibn.
November 7, 2025 — TOKYO - November 7, 2025 (NEWMEDIAWIRE) - Olympus Corporation (Olympus), a global MedTech leader dedicated to making people’s lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence. The strategy aims to accelerate cutting-edge technologies and reinforce Olympus’ global leadership in MedTech, improving outcomes for millions of patients worldwide.
November 7, 2025 — by Meg Flippin Benzinga DETROIT, MICHIGAN - November 7, 2025 (NEWMEDIAWIRE) - IQSTEL Inc. (NASDAQ: IQST), a global connectivity, AI and digital company focused on diversifying its revenue stream, expects double-digit organic revenue growth in 2026, with 26% topline growth.
November 7, 2025 — By Meg Flippin Benzinga DETROIT, MICHIGAN - November 7, 2025 (NEWMEDIAWIRE) - Cycurion Inc. (NASDAQ: CYCU), an IT cybersecurity solutions and AI company protecting government agencies and corporations including Fortune 100 and 500 companies, is closing out 2025 on a high note with $73.
November 7, 2025 — By Meg Flippin, Benzinga Cboe and Benzinga will host a virtual webinar introducing the Cboe Magnificent 10 Index (MGTN) on November 13 at 11 am ET. The Magnificent 7 paradigm is getting an upgrade with the addition of Advanced Micro Devices Inc.
November 7, 2025 — VANCOUVER, BRITISH COLUMBIA - November 6, 2025 (NEWMEDIAWIRE) - Trailbreaker Resources Ltd. (TBK.